Assessment of the availability of antiarrhythmic drugs

Анотація

Ischemic heart disease, which is one of the leading causes of mortality worldwide, is considered one of the main factors in the occurrence of arrhythmias. Military operations directly affect the quality of the pharmaceutical supply of drugs to the population, therefore the analysis of the availability of antiarrhythmic pharmacotherapeutic agents for Ukrainian patients is relevant. The aim of this work is to evaluate the availability of antiarrhythmic drugs used in cardiology practice. The official resources of the Ministry of Health of Ukraine and online data of pharmacy chains served as the information base of the study. Methods used: information search, analysis, generalization, marketing research. To assess the economic availability of antiarrhythmic drugs, for constant market positions, the solvency adequacy ratio was calculated. 37 trade names that are in the greatest demand have been identified. It has been established that domestically produced drugs remain significantly cheaper than foreign analogues, which makes Ukrainian generics more accessible to patients, but at the same time points to the potential exclusivity of imported drugs with patented technologies. In general, the availability of antiarrhythmic drugs on the market is deteriorating due to a combination of factors: the disappearance of certain trade names and rapid price growth, which can complicate the therapy of cardiac arrhythmias, especially in the context of the introduction of new regulations and requires monitoring to ensure a balance between pricing policy and the availability of innovative forms. The availability of antiarrhythmic drugs has significantly deteriorated. Average retail price growth between August 2024 and August 2025 was 69%, well above overall inflation in the pharmaceutical market, creating a financial barrier for patients. It is necessary to conduct further monitoring of the physical availability of drugs in pharmacies in different regions to ensure their uninterrupted supply in all regions of the country. Ukrainian generic drugs remain the most affordable for patients. The solvency adequacy ratio for domestic generics, such as Metoprolol tartrate and Aritmil, solution for injection, is less than 0.5%, which makes them much more affordable compared to imported original drugs, whose ratio can exceed 2%. State bodies and pharmaceutical companies should stimulate the production of domestic generic drugs.

Класифікація

Ідентифікатори

Схожі роботи